-+ 0.00%
-+ 0.00%
-+ 0.00%
LongBio Pharma says China regulator accepts LP-003 BLA for seasonal allergic rhinitis
Share
Listen to the news
LongBio Pharma says China regulator accepts LP-003 BLA for seasonal allergic rhinitis
  • LongBio Pharma’s China regulator accepted a BLA for LP-003 to treat seasonal allergic rhinitis.
  • LP-003 is an anti-IgE antibody developed for allergic diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12293421), on August 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending